184 related articles for article (PubMed ID: 26612407)
1. Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation.
Mori H; Suzuki H; Matsuzaki J; Tsugawa H; Fukuhara S; Miyoshi S; Hirata K; Seino T; Matsushita M; Masaoka T; Kanai T
Helicobacter; 2016 Aug; 21(4):286-94. PubMed ID: 26612407
[TBL] [Abstract][Full Text] [Related]
2. 10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy.
Mori H; Suzuki H; Matsuzaki J; Masaoka T; Kanai T
Digestion; 2020; 101(5):644-650. PubMed ID: 31387107
[TBL] [Abstract][Full Text] [Related]
3. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan.
Hirata Y; Ohmae T; Yanai A; Sakitani K; Hayakawa Y; Yoshida S; Sugimoto T; Mitsuno Y; Akanuma M; Yamaji Y; Ogura K; Maeda S; Koike K
Int J Antimicrob Agents; 2012 Apr; 39(4):352-5. PubMed ID: 22321702
[TBL] [Abstract][Full Text] [Related]
4. Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan.
Sugimoto M; Sahara S; Ichikawa H; Kagami T; Ban H; Otsuka T; Andoh A; Furuta T
Helicobacter; 2017 Feb; 22(1):. PubMed ID: 27213463
[TBL] [Abstract][Full Text] [Related]
5. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.
Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Uotani T; Sahara S; Ichikawa H; Yamada T; Osawa S; Sugimoto K; Watanabe H; Umemura K
J Gastroenterol Hepatol; 2014 Mar; 29(3):487-93. PubMed ID: 24224808
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen.
Hirata Y; Serizawa T; Shichijo S; Suzuki N; Sakitani K; Hayakawa Y; Yamada A; Koike K
Int J Infect Dis; 2016 Oct; 51():66-69. PubMed ID: 27590563
[TBL] [Abstract][Full Text] [Related]
7. High Helicobacter pylori cure rate with sitafloxacin-based triple therapy.
Sugimoto M; Sahara S; Ichikawa H; Kagami T; Uotani T; Furuta T
Aliment Pharmacol Ther; 2015 Aug; 42(4):477-83. PubMed ID: 26075959
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic resistance and
Mori H; Suzuki H; Matsuzaki J; Masaoka T; Kanai T
United European Gastroenterol J; 2017 Oct; 5(6):796-804. PubMed ID: 29026593
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.
Matsuzaki J; Suzuki H; Nishizawa T; Hirata K; Tsugawa H; Saito Y; Okada S; Fukuhara S; Hibi T
Antimicrob Agents Chemother; 2012 Mar; 56(3):1643-5. PubMed ID: 22203601
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Sue S; Shibata W; Sasaki T; Kaneko H; Irie K; Kondo M; Maeda S
J Gastroenterol Hepatol; 2019 Apr; 34(4):686-692. PubMed ID: 30151994
[TBL] [Abstract][Full Text] [Related]
11. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial.
Liou JM; Chen CC; Chen MJ; Chang CY; Fang YJ; Lee JY; Sheng WH; Wang HP; Wu MS; Lin JT
J Antimicrob Chemother; 2011 Aug; 66(8):1847-52. PubMed ID: 21632579
[TBL] [Abstract][Full Text] [Related]
12. Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.
Nishizawa T; Suzuki H; Nakagawa I; Iwasaki E; Masaoka T; Hibi T
J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S167-70. PubMed ID: 19120892
[TBL] [Abstract][Full Text] [Related]
13. Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea.
Lee JW; Kim N; Nam RH; Park JH; Kim JM; Jung HC; Song IS
Helicobacter; 2011 Aug; 16(4):301-10. PubMed ID: 21762270
[TBL] [Abstract][Full Text] [Related]
14. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.
Almeida N; Romãozinho JM; Donato MM; Luxo C; Cardoso O; Cipriano MA; Marinho C; Sofia C
Helicobacter; 2014 Apr; 19(2):90-7. PubMed ID: 24506175
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 May; 21(18):5568-74. PubMed ID: 25987781
[TBL] [Abstract][Full Text] [Related]
16. Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: a randomized pilot study.
Gu LY; Lin WW; Lu H; Chen XY; Ge ZZ; Li XB
Helicobacter; 2011 Aug; 16(4):284-8. PubMed ID: 21762267
[TBL] [Abstract][Full Text] [Related]
17. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication.
Di Caro S; Franceschi F; Mariani A; Thompson F; Raimondo D; Masci E; Testoni A; La Rocca E; Gasbarrini A
Dig Liver Dis; 2009 Jul; 41(7):480-5. PubMed ID: 18974025
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
Georgopoulos SD; Xirouchakis E; Martinez-Gonzalez B; Sgouras DN; Spiliadi C; Mentis AF; Laoudi F
Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study.
Kwon YH; Kim N; Lee JY; Choi YJ; Yoon K; Nam RH; Suh JH; Lee JW; Lee DH
Scand J Gastroenterol; 2016 Mar; 51(3):270-6. PubMed ID: 26452405
[TBL] [Abstract][Full Text] [Related]
20. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
Nista EC; Candelli M; Zocco MA; Cremonini F; Ojetti V; Finizio R; Spada C; Cammarota G; Gasbarrini G; Gasbarrini A
Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
